Lupin gets USFDA approval for generic version of Westcort cream to treat skin conditions

Published On 2019-08-18 04:16 GMT   |   Update On 2021-08-16 07:51 GMT

Hydrocortisone Valerate cream is a generic version of Sun Pharmaceutical Industries Ltd's Westcort cream in the same strength, Lupin added.


New Delhi: Drug firm Lupin on August 16 said it has received approval from the US health regulator for generic Hydrocortisone Valerate cream used for relief from inflammation and itching due to various skin conditions.


The company has got approval for its Hydrocortisone Valerate cream USP, 0.2 per cent from the United States Food and Drug Administration (USFDA), Lupin said in a filing to the BSE.


Also Read: Lupin gets USFDA nod for a generic version of Prozac tablets to treat depressive disorder


The product is a generic version of Sun Pharmaceutical Industries Ltd's Westcort cream in the same strength, it added.


The cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients, Lupin said.


Headquartered in Mumbai, Lupin's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. The company was founded in 1968 by Desh Bandhu Gupta, who was a professor of chemistry at BITS-Pilani, Rajasthan.


Also Read: USFDA completes inspection of Nagpur facility with no observations: Lupin

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News